T Cell News and Research

Latest T Cell News and Research

Rush University receives grants to study how epigenomic changes define cognitive decline

The National Institutes of Health has awarded Rush University Medical Center approximately $5.5 million in grants to study how epigenetic changes - chemical modifications to genes that result from diet, aging, stress, or environmental exposures - define and contribute to memory formation and cognitive decline. Results from the studies could profoundly alter the way the medical community understands, diagnoses, and treats Alzheimer's disease, according to the researchers.

1 Oct 2009

Gamida Cell publishes article evaluating Stemex for leukemia and lymphoma

Gamida Cell announced today the publication of an article evaluating carlecortemcel-l, the generic name of what is widely known as "StemEx", as a therapy for blood cancers such as leukemia and lymphoma. The article, carlecortemcel-l, an ex vivo expanded umbilical cord blood cell graft for allogeneic transplantation, written by Dr. Ka Wah Chan and Dr. Demetrios Petropoulos, will be published in the November 2009 issue of Expert Opinion on Biological Therapy.

1 Oct 2009

Risky driving behaviors linked to teens and parents interactions

Two new studies reveal that teen crashes and risky driving behaviors such as cell phone use, failure to wear seat belts, and drinking and driving are strongly linked with the way teens and parents communicate and approach rules about safety.

1 Oct 2009

Social environment plays vital role in breast cancer

Social environment can play an important role in the biology of disease, including breast cancer, and lead to significant differences in health outcome, according to results of a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

1 Oct 2009

Leading healthcare organizations choose DeviceAnywhere Test Center

As the Senate Finance Committee writes incentive bonuses for IT into the new “America’s Healthy Future Act” reform bill, there already exists a fast-growing roster of vendors and healthcare organizations delivering mobile applications that make health management more efficient, accessible, and cost-effective for the shared benefit of physicians, healthcare providers and consumers alike.

1 Oct 2009

New medical breakthrough by Bioheart for treatment of patients with heart disorders

Bioheart, Inc. offers yet another medical breakthrough with the next-level stem cell treatment for cardiac patients. The stem cells aid in limiting damage due to a cardiac event and promote angiogenesis or formation of new blood vessels.

1 Oct 2009

Stockholders approve BioSante Pharmaceuticals–Cell Genesys merger

BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc., today announced that BioSante stockholders have approved the merger between the two companies with BioSante as the surviving company.

1 Oct 2009

Latest optical and laser technology in medicine displayed at FiO meeting

From scopes that help premature babies breathe to techniques for imaging live neurons and beating hearts as they develop, the latest optical and laser technology being deployed in medicine and the biosciences will be on display at the Optical Society's (OSA) Annual Meeting, Frontiers in Optics (FiO), which takes place Oct. 11-15 at the Fairmont San Jose Hotel and the Sainte Claire Hotel in San Jose, Calif.

1 Oct 2009

National Institutes of Health awards $16.8 million grant to Hutchinson Center/UW group

The National Heart, Lung and Blood Institute of the National Institutes of Health has awarded a $16.8 million, seven-year grant to launch a bicoastal research partnership between Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium and Children's Hospital of Philadelphia.

30 Sep 2009

Immunocellular Therapeutics' pilot study can help in early cancer detection

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today results from its pilot study evaluating the cancer detection abilities of one of its lead monoclonal antibody product candidates, ICT-109. Data from this study demonstrated that ICT-109 had a statistically significant ability to discriminate between cancerous and non-cancerous samples, suggesting the potential to detect pancreatic and lung cancer in plasma and serum study sets.

30 Sep 2009

Orphan drug designation for pixantrone applied by Cell Therapeutics

Cell Therapeutics, Inc. ("CTI") announced today that it has applied to the European Medicines Agency (EMEA) for orphan drug designation for pixantrone. CTI initiated the process of obtaining marketing approval in Europe in July, 2009, for the treatment of relapsed or refractory aggressive NHL.

30 Sep 2009

Hologic's ThinPrep integrated imager receives CE marking approval

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced it has received CE marking approval for its ThinPrep® integrated imager.

From Hologic, Inc. 30 Sep 2009

NuGEN launches the Ovation WGA System for genome amplification

NuGEN Technologies Inc, a pace-setter in nucleic acid sample preparation, announces its entrance into the DNA market today with the Ovation WGA System, a linear, remarkably reliable, and more robust solution to whole genome amplification.

30 Sep 2009

Parathyroid gland transplants may prevent untreatable form of bone loss

An early laboratory success is taking University of Michigan researchers a step closer to parathyroid gland transplants that could one day prevent a currently untreatable form of bone loss associated with thyroid surgery.

30 Sep 2009

Critical biochemical pathways linked to the aging of human muscle identified

A study led by researchers at the University of California, Berkeley, has identified critical biochemical pathways linked to the aging of human muscle. By manipulating these pathways, the researchers were able to turn back the clock on old human muscle, restoring its ability to repair and rebuild itself.

30 Sep 2009

Tβ4 therapy in EAE mice improves neurological functional recovery

REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that researchers at the Henry Ford Health System in Detroit, Michigan, demonstrated for the first time that Tβ4 treatment of EAE (experimental autoimmune encephalomyelitis – an animal model for multiple sclerosis) significantly improves neurological functional recovery.

30 Sep 2009

University scientists achieve breakthrough in brain research

Chaos brews in the brains of newborns: the nerve cells are still bound only loosely to each other. Under the leadership of Academy Research Fellow Sari Lauri, a team of researchers at the University of Helsinki has been studying for years how a neural network capable of processing information effectively is created out of chaos. The team has now found a new kind of mechanism that adjusts the functional development of nerve cell contacts.

30 Sep 2009

Researchers identify embryonic origin of Merkel cells

Publication in Journal of Cell Biology : researchers from ULB (IRIBHM) identify the embryonic origin of Merkel cells. Their research continue on an extremely aggressive cancer, the Merkel cell carcinoma

30 Sep 2009

Genetic factors play an important role in the development of type 1 diabetes

Under the direction of Prof. Dr. Anette Ziegler, scientists of the Diabetes Research Group at Helmholtz Zentrum München and Technische Universität München investigated the formation of antibodies to a zinc transporter in children with elevated risk for type 1 diabetes. The study provided indications of an early onset of the disease when specific antibodies in the blood and specific variants of the associated zinc transporter are present in the genome.

30 Sep 2009

Plexxikon commences patient dosage in PLX4032 trials for metastatic melanoma

Plexxikon Inc. announces that enrollment has been initiated and the first patient has been treated in the first of two pivotal trials of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation occurring in about 50 percent of melanomas and about eight percent of all solid tumors.

30 Sep 2009